Retrospective Data Collection of Pediatric Patients With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) Treated With Caplacizumab
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Immune-mediated Thrombocytopenic Purpura
- Sponsor
- Sanofi
- Enrollment
- 4
- Locations
- 1
- Primary Endpoint
- Proportion of subjects with recurrent disease
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this multi-country, retrospective data collection study (chart review) is to describe the effectiveness and safety of caplacizumab in pediatric patients with iTTP.
Detailed Description
Pediatric patients who received caplacizumab will be identified for enrollment in the chart review. The eligibility period starts on August 30, 2018 in the United Kingdom (UK) and France and February 6, 2019 for the United States (US). Data collection is fully retrospective and will be anchored to the patient's index event date. The index event date is defined as the date the patient initiated caplacizumab treatment. The study period begins at the index date and ends at the earliest date of chart abstraction initiation, 12 weeks after last dose of caplacizumab treatment, date of death, or loss to follow-upwhich ever comes first .
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient's aged ≤18 years at start of caplacizumab treatment initiation
- •Patient has a diagnosis of iTTP documented in the medical records
- •Patient was treated with caplacizumab within the eligibility period
Exclusion Criteria
- •Patient declined use of data for study (where local regulations require patient notification of planned study)
- •Patient's medical chart is missing or not retrievable
Outcomes
Primary Outcomes
Proportion of subjects with recurrent disease
Time Frame: From index date up to 12 weeks after last dose of caplacizumab
Proportion of subjects with iTTP exacerbation (defined as recurrence within 30 days after last PE) and Proportion of subjects with iTTP relapse (defined as recurrence more than 30 days after last PE)
Total duration of hospitalization stays
Time Frame: From index date up to 12 weeks after last dose of caplacizumab
Proportion of patients achieving clinical response
Time Frame: From index date up to 12 weeks after last dose of caplacizumab
defined as a normal platelet countand LDH \< 2 ULN for at least 48 hours following initial normalization or response of platelet count
Platelet count response
Time Frame: From index date up to 12 weeks after last dose of caplacizumab
defined as time from caplacizumab initiation to initial platelet count ≥ 150×109/L with subsequent stop of daily plasma exchange (PE) within 5 days
Proportion of subjects with refractory iTTP
Time Frame: From index date up to 12 weeks after last dose of caplacizumab
defined as lack of doubling of platelet count after four days of caplacizumab treatment and a lactate dehydrogenase (LDH) level that remained above the upper limit of normal (ULN) range
Number of participants with Adverse event
Time Frame: From index date up to 12 weeks after last dose of caplacizumab
including serious adverse events
Time to normalization of organ damage marker levels
Time Frame: From index date up to 12 weeks after last dose of caplacizumab
Defined asLDH ≤ 2 x ULN, Serum creatinine ≤ 1 x ULN, Cardiac troponin I ≤ 1 x ULN
Duration of intensive care unit (ICU) stay
Time Frame: From index date up to 12 weeks after last dose of caplacizumab
Duration of therapeutic PE
Time Frame: From index date up to 12 weeks after last dose of caplacizumab
Time to ADAMTS13 activity ≥ 20%
Time Frame: From index date up to 12 weeks after last dose of caplacizumab
where available and feasible
Secondary Outcomes
- Treatment pattern of caplacizumab therapy(From index date up to 12 weeks after last dose of caplacizumab)
- Types and duration of concomitant medications(From index date up to 12 weeks after last dose of caplacizumab)